We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Pfizer Seeks to Develop OTC Lipitor Product

By LabMedica International staff writers
Posted on 15 Aug 2011
Print article
Pharmaceutical giant Pfizer (New York, NY, USA) is planning to introduce an over-the-counter (OTC) version of Lipitor, the world's best-selling drug, after it loses patent protection in November 2011.

Pfizer has not yet determined whether the US Food and Drug Administration (FDA) would allow the drug to be sold without a prescription. To tackle this issue, the company has assembled a team of experts to examine the feasibility of a switch to OTC sales, as well as other options for the medicine. Selling an OTC version of the drug without a prescription would allow Pfizer to retain some of the US$11 billion in annual revenue that Lipitor has been generating.

The company would first have to convince the FDA that consumers could take the drug without a doctor's supervision. Prescription-to-OTC switches, however, have been rare in recent years, but some have been commercially successful, including Johnson & Johnson's (JNJ; New Brunswick, NJ, USA) launch of an OTC version of allergy drug Zyrtec after Pfizer's prescription version lost patent protection, as well as the Merck (Whitehouse Station, NJ, USA) allergy pill Claritin, which it inherited through its acquisition of Schering-Plough.

“In order to sell Lipitor without a prescription, Pfizer must show that patients can safely diagnose themselves and use the drug properly; no cholesterol-lowering drug, or statin, has been able to do that,” said Shelly Burgess, a spokeswoman for the FDA. “They would have to provide data to show that consumers understand the treatment and recognize that cholesterol monitoring is required. In previous studies most study participants made mistakes and chose to take the proposed over-the-counter statin when they should not have done that.”

Lipitor, the trade name of atorvastatin, is a member of the drug class known as statins, used for lowering blood cholesterol; like all statins, it works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. Lipitor also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms.

Related Links:

Pfizer
Johnson & Johnson's
Merck


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
Benchtop Cooler
PCR-Cooler & PCR-Rack

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.